Clinical Research Directory

Key Inclusion Criteria: * Age: ≥ 18 years * Mental Capacity: Individual should be able to give informed consent, if alive * Triple Negative Breast Cancer (TNBC) * Oestrogen receptor (ER) negative with an Allred score of ≤ 2 or, equivalent pathology scoring system e.g., ≤10% (0 - 10%) tumour nuclei staining * HER2 negative: 1+ on immunohistochemistry or 2+ immunohistochemistry and FISH/D-Dish negative * Progesterone receptor (PgR) negative = PgR score of ≤2 or equivalent pathology scoring system e.g., ≤10% (0 - 10%) tumour nuclei staining * Androgen receptor (AR) status (if known): negative or positive * TNBC phenotype: HER2 negative tumours with borderline ER or PgR scoring on immunohistochemistry e.g., ER 3/8 and PgR 0/3 negative which were managed as early TNBC can be included but should be discussed on a case-by-case basis prior to study registration with Principal Investigator. * Lymph node involvement: Lymph node negative or positive; any number including clinical/pathological N3 involvement (TNM staging ≥ V.8.0) * Cancer Staging: Stage 2 or stage 3 breast cancer * Treated considered standard of care neoadjuvant chemotherapy: an anthracycline, a taxane, an alkylating agent, +/- a platinum, +/- immunotherapy * Available archival tissue samples Key Exclusion Criteria: * Stage IV de novo metastatic breast cancer are not eligible * Stage I breast cancers are not eligible * Women who were diagnosed with more than one cancer type within 3 years of the breast cancer diagnosis of TNBC are not eligible * Received neoadjuvant radiotherapy * Received neoadjuvant endocrine treatment * Women pregnant at the time of the TNBC diagnosis * Significant medical co-morbidities which could have influenced the participant's prognosis are excluded. Examples include cardiac failure, moderate - severe renal failure, active hepatitis, HIV, active TB, ischaemic heart disease etc.